Eszter Kacskovics

Eszter Kacskovics is currently the Public Affairs Director of SCA Hygiene Products, Incontinence Care Europe. She has been working in the health care sector for more than 17 years, and prior to the current role, she had commercial and controlling responsibilities. She is the chairman of the Eucomed Community care sector group (CCSG), and CCSG’s representative in the Eucomed Board.  CCSG aims at enabling the industry to understand the healthcare environment around community care, and to collaborate with suitable stakeholders in a structured and long-term way to create understanding, share best-practice and bring solutions.

Editors’ Note: This blog is part 2 of a series on the MEAT value-based procurement project, an initiative that advocates towards a shift from price-based procurement of medical technology towards value-based procurement. It does so by defining a Most Economically Advantageous Tendering (MEAT) framework that includes the value of medical technologies, services and solutions in procurement processes across Europe. Read part 1 and part 3 . If you would like to contribute please contact the MedTech Views editorial team at info@medtechviews.eu . Earlier this year you could read about a new partnership between MedTech Europe and BCG where the aim was to define a framework for Most Economically Advantageous Tendering (MEAT) for the medical technology industry. Since then a few months have passed by, and I was really happy to see the first results of this partnership during the gathering of procurement officials in Lisbon end of September. The new MEAT framework presents a new way of thinking towards what the future should look like: a new era where the main role of procurement is to secure best value for money, and not only focus on the lowest possible price. During the last few years, extra pressure has arised due to crunching budgets, and at the same time procurement practices have not been very successful in taking into account the benefit of innovation in medical technology. Lower price does not automatically lead to lower cost, and several innovations have proven to lead to lower overall costs despite higher purchase price. Medical technology innovation will not stop. However, we can –at best- only expect to have the same levels of funding in the future. Therefore, if we want a different outcome, we have to act differently. Having a new methodology for procurement processes is definitely a must, but will that alone...
When it comes to speaking about diseases and their impact on patients, carers and families, we don’t normally jump at the chance to talk about incontinence. Many people are embarrassed to discuss it – whether it be from their own experience, from supporting family members suffering from it, or because it just isn’t as sexy as diabetes and cardiovascular disease (which have similar prevalence rates). But we need to talk about incontinence.
Incontinence
Incontinence is a condition that often gets associated with age. When we think about incontinence we tend to think first about elderly people and that’s normal because over 60% of nursing home residents are affected with some kind of incontinence (from mild to severe). However, European studies estimate that between 4% and 8% of the total population are affected, regardless of age. As our populations grow older, it is fair to say that more and more people will suffer from it. This could be your neighbour’s condition and you wouldn’t even know about it!